Luís Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luís Santos has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
André Caetano
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisbon, Portugal; CEDOC Chronic Diseases Research Centre, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
2 shared publications- Marco Fernandes
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisbon, Portugal
2 shared publications - Anabela Matos
Neurology Department, ULS Coimbra, Coimbra, Portugal
1 shared publication - Andreia Veiga
Serviço de Neurologia. Unidade Local de Saúde de Trás-os-Montes e Alto Douro. Vila Real
1 shared publication - Catarina Falcão de Campos
Department of Neurology Hospital Santa Maria Lisbon Portugal
1 shared publication Elmira Medeiros
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, 1349-019, Lisbon, Portugal; CEDOC Chronic Diseases Research Centre, Nova Medical School / Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (1) , 62-75
Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis
Myasthenia gravis is an autoimmune disease that affects the neuromuscular junction, mainly through the action of pathogenic antibodies such as those directed against the nicotinic acetylcholine receptor or, more infrequently, against the muscle specific kinase. Other important components of the autoimmune process include the complement pathway and B and T cell populations. Diagnosis is based on the finding of fatigable muscle weakness, which can affect several muscle groups, either in isolation or in variable combinations. Neurophysiological techniques and/or the detection of pathogenic antibodies in serum are also essential for the diagnosis of myasthenia gravis. Maintenance treatment was traditionally based on corticosteroids and non-steroidal immunosuppressants. Recently approved drugs, such as the terminal complement pathway inhibitors and the neonatal Fc receptor antagonists, are reshaping the treatment landscape, supported by robust evidence of an excellent combination of efficacy and safety. Although several international guidelines have been published in the last decade, some key questions remain without precise guidance. Hence, a group of nine experts from the Portuguese Neuromuscular Society has elaborated consensus guidelines that aim to provide detailed guidance on diagnostic workup and treatment, grounded both in published evidence and in clinical experience. Key novel aspects include step-by-step instructions for diagnostic workup, a set of diagnostic criteria, guidance on the use of complement inhibitors and neonatal Fc receptor antagonists, and tailored treatment algorithms according to antibody subgroup and clinical severity.
- 15 December 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (1) , 62-75
Open AccessPortuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis
Myasthenia gravis is an autoimmune disease that affects the neuromuscular junction, mainly through the action of pathogenic antibodies such as those directed against the nicotinic acetylcholine receptor or, more infrequently, against the muscle specific kinase. Other important components of the autoimmune process include the complement pathway and B and T cell populations. Diagnosis is based on the finding of fatigable muscle weakness, which can affect several muscle groups, either in isolation or in variable combinations. Neurophysiological techniques and/or the detection of pathogenic antibodies in serum are also essential for the diagnosis of myasthenia gravis. Maintenance treatment was traditionally based on corticosteroids and non-steroidal immunosuppressants. Recently approved drugs, such as the terminal complement pathway inhibitors and the neonatal Fc receptor antagonists, are reshaping the treatment landscape, supported by robust evidence of an excellent combination of efficacy and safety. Although several international guidelines have been published in the last decade, some key questions remain without precise guidance. Hence, a group of nine experts from the Portuguese Neuromuscular Society has elaborated consensus guidelines that aim to provide detailed guidance on diagnostic workup and treatment, grounded both in published evidence and in clinical experience. Key novel aspects include step-by-step instructions for diagnostic workup, a set of diagnostic criteria, guidance on the use of complement inhibitors and neonatal Fc receptor antagonists, and tailored treatment algorithms according to antibody subgroup and clinical severity.
- 1 September 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 208, 106829
Characterization of a Portuguese family with Charcot-Marie-Tooth disease type 1E due to a novel point mutation in the PMP22 gene
- 1 September 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 208, 106829
Characterization of a Portuguese family with Charcot-Marie-Tooth disease type 1E due to a novel point mutation in the PMP22 gene
- 1 April 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 203, 106591
Diagnosis of DOK7 congenital myasthenic syndrome during pregnancy: A case report and literature review
- 1 April 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 203, 106591
Diagnosis of DOK7 congenital myasthenic syndrome during pregnancy: A case report and literature review